Background: Lithium augmentation is widely applied for treatment-resistant depression, however, the clinical predictors of its efficacy regarding polarity and bipolarity are unknown.

Methods: We retrospectively examined the predictive value of clinical variables in 79 depressed patients who underwent lithium augmentation after failure to respond to antidepressant monotherapy. Lithium augmentation efficacy was evaluated by Clinical Global Impression Improvement assessment 4 to 8 weeks after initiating lithium administration; subjects with scores of 1 and 2 were defined as responders, and those with scores of 3 to 7 as non-responders. Clinical variables, including demographic and diagnostic variables, psychiatric medication, and clinical variables, were compared between groups. The bipolarity of patients with major depressive disorder as a final diagnosis was evaluated in association with the lithium augmentation efficacy. Data were analyzed using a chi-square test or Fisher's test.

Results: The lithium augmentation efficacy rate was 41% among 79 enrolled patients (14 dropped out, 32 responders, and 33 non-responders). Lithium augmentation was significantly more effective for patients with a final diagnosis of bipolar disorder than with major depressive disorder (p=0.03). Subjects with more than three major depressive episodes showed a significant response to lithium augmentation (p=0.004). The rate of a family history of major depressive disorder/bipolar disorder in a first-degree relative was significantly higher in responders (34%) than in non-responders (7%, p=0.01), consistent with the association between the efficacy of lithium augmentation and bipolarity in major depressive disorder (responders=27% vs. non-responders=3%, p=0.03).

Limitation: The study was retrospective and severity was not analyzed.

Conclusion: Bipolar disorder, frequency of major depressive episodes, and family history of major depressive disorder/bipolar disorder in a first-degree relative were detected as predictors of lithium augmentation efficacy. Among them, family history of major depressive disorder/bipolar disorder in a first-degree relative was the most reliable predictor of lithium augmentation efficacy for bipolar disorder and major depressive disorder.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jad.2009.12.025DOI Listing

Publication Analysis

Top Keywords

lithium augmentation
44
major depressive
36
augmentation efficacy
20
depressive disorder
16
lithium
12
clinical variables
12
bipolar disorder
12
family history
12
history major
12
depressive disorder/bipolar
12

Similar Publications

LiTiO (LTO) batteries are known for safety and long lifespan due to zero-strain and stable lattice. However, their low specific capacity and lithium-ion diffusion limit practical use. This study explored modifying LTO through yttrium doping by hydrothermal method to form LiYTiO nanoparticles.

View Article and Find Full Text PDF

Enhancement of neuronal plasticity by small-molecule therapeutics protects cognitive skills and also ameliorates progressive neurodegenerative pathologies like Alzheimer's disease (AD) and dementia. One such compound, a novel histone deacetylase 2 (HDAC2) inhibitor named JRM-28, was shown here to enhance dendritic strength, augment spine density, and upregulate post-synaptic neurotransmission in hippocampal neurons. The molecular basis for this effect correlates with JRM-28-induced upregulation of the transcription of cAMP response element-binding protein(CREB), induction of its transcriptional activity, and subsequent stimulation of expressions of CREB-dependent plasticity-associated genes, such as those encoding N-methyl-D-aspartate (NMDA) receptor subunit NR2A and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunit GluR1.

View Article and Find Full Text PDF

Depression is a common disease that affects 3.8% of the global population. Despite various antidepressant treatments, one-third of patients do not respond to antidepressants, therefore augmentation with mood stabilizers such as lithium may be required in this group.

View Article and Find Full Text PDF

PVA-enhanced green synthesis of CMC-based lithium adsorption films.

Carbohydr Polym

February 2025

Key Laboratory of Bio-based Material Science and Technology, Ministry of Education, Northeast Forestry University, Harbin 150040, China.

The titanium-based lithium ion sieve (HTO), renowned for its exceptional adsorption performance and cyclic stability, was utilized in addressing the global shortage of lithium resources. However, the recovery and reuse efficiency of HTO in powder form is relatively low, which limits its application in industrial fields. To address this issue, this study utilized carboxymethyl cellulose (CMC) as the principal matrix material, while polyvinyl alcohol (PVA) played a dual function as both matrix and crosslinker, negating the necessity for supplementary crosslinking materials.

View Article and Find Full Text PDF

Context: Battery interface research can effectively guide battery design and material selection to improve battery performance. However, current electrode material interface studies still have significant limitations. In this paper, by employing DFT-D method, the influences of doping elements (boron, nitrogen, phosphorus, sulfur, and silicon) on the properties of C fullerene, such as structural stability, electronic properties, and the adsorption and migration of lithium ion, are comprehensively investigated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!